What is the official website of Roche Diagnostics USA ?

The official website of Roche Diagnostics USA is https://usdiagnostics.roche.com.

What is Roche Diagnostics USA's cybersecurity risk score?

Roche Diagnostics USA has an AI-generated cybersecurity risk score of 750 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Roche Diagnostics USA experienced?

According to Rankiteo, Roche Diagnostics USA currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Roche Diagnostics USA been affected by any supply chain cyber incidents ?

According to Rankiteo, Roche Diagnostics USA has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Roche Diagnostics USA have SOC 2 Type 1 certification ?

According to Rankiteo, Roche Diagnostics USA is not certified under SOC 2 Type 1.

Does Roche Diagnostics USA have SOC 2 Type 2 certification ?

According to Rankiteo, Roche Diagnostics USA does not hold a SOC 2 Type 2 certification.

Does Roche Diagnostics USA comply with GDPR ?

According to Rankiteo, Roche Diagnostics USA is not listed as GDPR compliant.

Does Roche Diagnostics USA have PCI DSS certification ?

According to Rankiteo, Roche Diagnostics USA does not currently maintain PCI DSS compliance.

Does Roche Diagnostics USA comply with HIPAA ?

According to Rankiteo, Roche Diagnostics USA is not compliant with HIPAA regulations.

Does Roche Diagnostics USA have ISO 27001 certification ?

According to Rankiteo,Roche Diagnostics USA is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Roche Diagnostics USA operate in ?

Roche Diagnostics USA operates primarily in the Biotechnology Research industry.

How many employees does Roche Diagnostics USA have ?

Roche Diagnostics USA employs approximately 16 people worldwide.

Does Roche Diagnostics USA own any subsidiaries ?

Roche Diagnostics USA presently has no subsidiaries across any sectors.

How many LinkedIn followers does Roche Diagnostics USA have ?

Roche Diagnostics USA's official LinkedIn profile has approximately 110,338 followers.

What is the NAICS classification code for Roche Diagnostics USA ?

Roche Diagnostics USA is classified under the NAICS code 541714, which corresponds to Research and Development in Biotechnology (except Nanobiotechnology).

Does Roche Diagnostics USA have a Crunchbase profile ?

No, Roche Diagnostics USA does not have a profile on Crunchbase.

Does Roche Diagnostics USA have a LinkedIn profile ?

Yes, Roche Diagnostics USA maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/roche-diagnostics-usa.

How many cybersecurity incidents has Roche Diagnostics USA experienced ?

As of July 26, 2026, Rankiteo reports that Roche Diagnostics USA has not experienced any cybersecurity incidents.

How many peer or competitor companies does Roche Diagnostics USA have ?

Roche Diagnostics USA has an estimated 4,731 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

RDU

Boost Score +25 with badge (5 left)

750

/1000

Fair

775

/1000

Fair

Roche Diagnostics USA Vendor Cyber Rating & Cyber Score

roche.com

Add Your Compliance Badge

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche Diagnostics is the world leader in in-vitro diagnostics. Working at Roche means working at the forefront of innovation. Our cutting-edge technologies and healthcare solutions were occasionally developed with unconventional methods but always with the highest standard of quality in mind. Our Roche Diagnostics USA offices are located in: • Boston (MA) • Branchburg (NJ) • Indianapolis (IN) • Pleasanton (CA) • Santa Clara (CA) • San Jose (CA) • Seattle (WA) • Tucson (AZ) Follow our page to be kept up to date with news about Roche Diagnostics in the

RDU A.I CyberSecurity Scoring

Scoring History

RDU

Roche Diagnostics USA CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

RDU Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for RDU

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Roche Diagnostics USA in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Roche Diagnostics USA in 2026.

Incident Types RDU vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for Roche Diagnostics USA in 2026.

Incident History - RDU (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Roche Diagnostics USA Subsidiaries

RDU

Biotechnology Research

Website: https://usdiagnostics.roche.com

Company Size: 5,001-10,000 employees

RocheBiotechnology Research

GenentechBiotechnology Research

Genentech MedicalBiotechnology Research

Roche MéxicoPharmaceutical Manufacturing

Roche Middle EastBiotechnology Research

Roche DeutschlandBiotechnologieforschung

Loading…

Roche Diagnostics USA Similar Companies

Avantor

cb avantorsciences.com

Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.

bioMérieux

biomerieux.com

A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.

ICON plc

iconplc.com

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

Eurofins

cb eurofins.com

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

Roche

cb roche.com

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

CSL

cb csl.com

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra

The National Institutes of Health

cb nih.gov

NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement

Gilead Sciences

cb gilead.com

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines

Fortrea

fortrea.com

Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com

Loading…

NEWS

Roche Diagnostics USA CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

November 19, 2025 08:00 AM

Freenome and Roche partner on cancer screening technology for ex-US markets

Freenome has announced a strategic agreement with Roche aimed at commercialising its cancer screening technology outside the US.

Read Article

April 24, 2025 07:00 AM

Roche seeks US tariff relief in direct talks with Trump administration

Swiss drugmaker Roche is petitioning the U.S. government in direct talks for import tariff exemptions, arguing the products it ships into...

Read Article

April 22, 2025 07:00 AM

Roche to invest $50 billion in the U.S. as pharma tariff threat lingers

Swiss pharmaceutical giant Roche on Tuesday said that it would invest $50 billion in the United States.

Read Article

September 26, 2024 07:00 AM

Health data must be protected to secure a healthier future

Cybersecurity is no longer optional. It is central for new technologies to become a building block of ethical, safe, and patient-centered...

Read Article

March 27, 2023 07:00 AM

Preparing for tomorrow’s diagnostics industry today

How companies could leverage diagnostics industry trends to help shape the future of health care delivery—if they start planning now.

Read Article

March 13, 2020 07:00 AM

US gives emergency approval for Roche coronavirus test in the race to boost screening capacity

The U.S. Food and Drug Administration issued emergency authorization for a coronavirus test made by Swiss diagnostics maker Roche,...

Read Article

April 06, 2014 07:00 AM

Roche buys U.S. diagnostics company IQuum in $450 million deal

Swiss drugmaker Roche has agreed to buy privately-held U.S. diagnostics company IQuum in a deal worth up to $450 million (271...

Read Article

January 05, 2005 08:00 AM

Roche Diagnostics PCR Diagnostic Kits

Roche Diagnostics completed the construction and commissioning of a new manufacturing facility in Branchburg, New Jersey...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-10681

SUMMARY

In Zephyr's userspace dynamic-objects subsystem, thread_idx_alloc() in kernel/userspace/userspace.c allocated a new thread permission index from the global _thread_idx_map[] bitmap without holding lists_lock. On SMP systems, two user-mode threads invoking the k_object_alloc(K_OBJ_THREAD) syscall concurrently can both observe the same low free bit, perform the same non-atomic RMW to clear it, and return the identical tidx. The two newly created K_OBJ_THREAD objects are then assigned the same thread_id, so the two user threads alias a single bit position in every kernel object's perms[] bitfield: any subsequent grant of access on a kernel object to one thread is implicitly a grant to the other, defeating userspace ACL isolation. A secondary lost-update window between the unlocked &=~BIT() in alloc and the locked |= BIT() in thread_idx_free() can also leak entries from the thread-index pool. The defect is reachable from any user-mode thread via the unrestricted __syscall k_object_alloc and is gated on CONFIG_USERSPACE, CONFIG_DYNAMIC_OBJECTS, and CONFIG_SMP. The flaw was introduced when the per-thread permission index was added in 2018 and is present in every release up to and including v4.4.0. Fixed by holding lists_lock across the bitmap RMW and the permissions clear (and inlining the obj_list traversal that previously took the lock itself).

Published

Date2026-07-25

Updated

Date2026-07-25

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: HIGH

CVSS:3.1/AV:L/AC:H/PR:L/UI:N/S:U/C:H/I:H/A:L

Impact Score

5.5

Exploitability

REFERENCES

CVE-2026-66013

SUMMARY

OpenRemote before 1.26.2 contains an authentication bypass vulnerability in the console registration API that allows unauthenticated attackers to update existing console assets by supplying a known asset identifier. Attackers can overwrite push notification tokens and console metadata without authentication or ownership validation, redirecting notifications or denying delivery to legitimate consoles.

Published

Date2026-07-25

Updated

Date2026-07-25

RISK INFORMATION (Score: )

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-66012

SUMMARY

SiYuan before v3.7.2 contains a missing authorization vulnerability in the POST /mcp kernel endpoint, which is gated only by a general auth check (model.CheckAuth) with no admin-role or read-only enforcement. This exposes 31 MCP tools, including a file tool with list/read/write/delete/rename/copy actions across the entire workspace. When the Publish server is enabled in anonymous mode (Conf.Publish.Enable=true and Conf.Publish.Auth.Enable=false), the Publish reverse proxy attaches an anonymous RoleReader JWT to proxied requests, allowing a remote unauthenticated attacker to reach /mcp. The attacker can read conf/conf.json to extract accessAuthCode, api.token, and cookieKey in plaintext, write arbitrary files in the workspace, and plant a plugin into data/plugins/ that executes with nodeIntegration:true and no contextIsolation on the next desktop launch, leading to administrator takeover.

Published

Date2026-07-25

Updated

Date2026-07-25

RISK INFORMATION (Score: 10)

cvss3

Base Score: 10.0

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 10.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.9

REFERENCES

CVE-2026-66011

SUMMARY

ImageMagick before 7.1.2-27 contains a memory leak vulnerability in the magick command-line interface when invalid options are provided. Attackers can trigger memory exhaustion by repeatedly supplying malformed command-line arguments to consume system resources.

Published

Date2026-07-25

Updated

Date2026-07-25

RISK INFORMATION (Score: 3.3)

cvss3

Base Score: 3.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:N/I:N/A:L

cvss4

Base Score: 4.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:P/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.8

REFERENCES

CVE-2026-64529

SUMMARY

In the Linux kernel, the following vulnerability has been resolved: crypto: qat - remove unused character device and IOCTLs The QAT driver exposes a character device (qat_adf_ctl) with IOCTLs for device configuration, start, stop, status query and enumeration. These IOCTLs are not part of any public uAPI header and have no known in-tree or out-of-tree users. Device lifecycle is already managed via sysfs. The ioctl interface also increases the attack surface and is the subject of a number of bug reports. Remove the character device, the IOCTL definitions, and the related data structures (adf_dev_status_info, adf_user_cfg_key_val, adf_user_cfg_section, adf_user_cfg_ctl_data). Drop the now-unused adf_cfg_user.h header and strip adf_ctl_drv.c down to the minimal module_init/module_exit hooks for workqueue, AER, and crypto/compression algorithm registration. Clean up leftover dead code that was only reachable from the removed IOCTL paths: adf_cfg_del_all(), adf_devmgr_verify_id(), adf_devmgr_get_num_dev(), adf_devmgr_get_dev_by_id(), adf_get_vf_real_id() and the unused ADF_CFG macros. Additionally, drop the entry associated to QAT IOCTLs in ioctl-number.rst.

Published

Date2026-07-25

Updated

Date2026-07-25

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…